Bio-Rad Laboratories, Inc. (BIO) EV/EBITDA Ratio: 254.89x
Is Bio-Rad Laboratories, Inc.’s EV/EBITDA ratio high or low?
Bio-Rad Laboratories, Inc.'s EV/EBITDA ratio of 254.89x is 428% above its 5-year average of 48.31x, near the high end of its 5-year range (1.88x–273.11x).
The EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO) is 254.89x as of Thursday, June 11, 2026. It is above its 12-month average by 330.03% (59.27x).
BIO EV/EBITDA Ratio Chart
BIO Average EV/EBITDA Ratio Chart
BIO Current vs Average EV/EBITDA Ratio Chart
BIO EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
254.89x
EV/EBITDA RATIO AVG TTM
59.27x
EV/EBITDA RATIO AVG 3Y
93.59x
EV/EBITDA RATIO AVG 5Y
48.31x
EV/EBITDA RATIO AVG 10Y
24.06x
EV/EBITDA RATIO AVG 15Y
18.23x
EV/EBITDA RATIO AVG 20Y
15.83x
CURRENT VS TTM AVG
+330.03%
CURRENT VS 3Y AVG
+172.35%
CURRENT VS 5Y AVG
+427.65%
CURRENT VS 10Y AVG
+959.34%
CURRENT VS 15Y AVG
+1298.48%
CURRENT VS 20Y AVG
+1509.83%
BIO Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 254.89x | 59.27x | 93.59x | 48.31x |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | 14.86x | 19.01x | 15.54x | 17.40x |
| Hims & Hers Health, Inc. (HIMS) | $6.42B | 74.96x | 67.13x | 332.36x | 332.36x |
| Baxter International Inc. (BAX) | $10.49B | 24.37x | 20.31x | 19.09x | 19.10x |
| Align Technology, Inc. (ALGN) | $12.27B | 13.98x | 13.90x | 20.40x | 25.86x |
| Hologic, Inc. (HOLX) | $16.97B | 17.28x | 15.01x | 15.35x | 12.41x |
| Moderna, Inc. (MRNA) | $18.71B | N/A | 12.39x | 25.27x | 25.27x |
| BioNTech SE (BNTX) | $21.92B | N/A | 51.40x | 19.63x | 20.05x |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 20.23x | 23.55x | 23.87x | 26.49x |
| Waters Corporation (WAT) | $23.60B | 37.66x | 21.66x | 21.26x | 21.46x |
EV/EBITDA vs. its own history
At 254.9, EV/EBITDA is richer than usual — richer than 100% of its 20-year range.
20-year low
1.9
median
10.2
20-year high
273.1
Understanding EV/EBITDA
Enterprise Value (EV) = Market Cap + Total Debt - Cash
EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization
EV/EBITDA is commonly used for comparing companies because:
- It accounts for debt levels (capital structure neutral)
- It removes effects of different depreciation policies
- It can be compared across countries with different tax rates
- It can remain available when net income is negative, if EBITDA is positive
Bio-Rad Laboratories, Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The EV/EBITDA ratio for BIO stock is 254.89x.
- Is Bio-Rad Laboratories, Inc.'s EV/EBITDA ratio high or low?
- Bio-Rad Laboratories, Inc.'s EV/EBITDA ratio of 254.89x is 428% above its 5-year average of 48.31x, near the high end of its 5-year range (1.88x–273.11x).
- What is the TTM average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average EV/EBITDA ratio for BIO stock is 59.27x.
- What is the 3Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average EV/EBITDA ratio for BIO stock is 93.59x.
- What is the 5Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average EV/EBITDA ratio for BIO stock is 48.31x.
- What is the 10Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average EV/EBITDA ratio for BIO stock is 24.06x.
- What is the 15Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average EV/EBITDA ratio for BIO stock is 18.23x.
- What is the 20Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average EV/EBITDA ratio for BIO stock is 15.83x.
Bio-Rad Laboratories, Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-11 | 254.89x |
| 2026-06-10 | 251.91x |
| 2026-06-09 | 256.71x |
| 2026-06-08 | 252.14x |
| 2026-06-05 | 254.49x |
| 2026-06-04 | 264.73x |
| 2026-06-03 | 262.68x |
| 2026-06-02 | 263.69x |
| 2026-06-01 | 263.17x |
| 2026-05-29 | 268.64x |
| 2026-05-28 | 273.11x |
| 2026-05-27 | 263.03x |
| 2026-05-26 | 256.50x |
| 2026-05-22 | 249.36x |
| 2026-05-21 | 248.58x |
| 2026-05-20 | 249.45x |
| 2026-05-19 | 244.15x |
| 2026-05-18 | 244.75x |
| 2026-05-15 | 218.03x |
| 2026-05-14 | 217.05x |
| 2026-05-13 | 214.90x |
| 2026-05-12 | 213.50x |
| 2026-05-11 | 215.12x |
| 2026-05-08 | 223.32x |
| 2026-05-07 | 225.66x |
| 2026-05-06 | 226.98x |
| 2026-05-05 | 225.50x |
| 2026-05-04 | 226.08x |
| 2026-05-01 | 225.06x |
| 2026-04-30 | 243.42x |
| 2026-04-29 | 9.97x |
| 2026-04-28 | 10.10x |
| 2026-04-27 | 10.36x |
| 2026-04-24 | 10.38x |
| 2026-04-23 | 10.17x |
| 2026-04-22 | 10.79x |
| 2026-04-21 | 10.95x |
| 2026-04-20 | 10.87x |
| 2026-04-17 | 10.73x |
| 2026-04-16 | 10.48x |
| 2026-04-15 | 10.64x |
| 2026-04-14 | 10.52x |
| 2026-04-13 | 10.39x |
| 2026-04-10 | 10.10x |
| 2026-04-09 | 10.05x |
| 2026-04-08 | 10.16x |
| 2026-04-07 | 10.06x |
| 2026-04-06 | 10.09x |
| 2026-04-02 | 10.13x |
| 2026-04-01 | 10.07x |
| 2026-03-31 | 10.09x |
| 2026-03-30 | 9.82x |
| 2026-03-27 | 9.66x |
| 2026-03-26 | 10.02x |
| 2026-03-25 | 9.92x |
| 2026-03-24 | 9.87x |
| 2026-03-23 | 9.65x |
| 2026-03-20 | 9.63x |
| 2026-03-19 | 9.65x |
| 2026-03-18 | 9.74x |
| 2026-03-17 | 9.79x |
| 2026-03-16 | 9.53x |
| 2026-03-13 | 9.58x |
| 2026-03-12 | 9.55x |
| 2026-03-11 | 9.80x |
| 2026-03-10 | 9.74x |
| 2026-03-09 | 9.85x |
| 2026-03-06 | 9.80x |
| 2026-03-05 | 10.10x |
| 2026-03-04 | 10.28x |
| 2026-03-03 | 10.13x |
| 2026-03-02 | 10.11x |
| 2026-02-27 | 10.08x |
| 2026-02-26 | 9.97x |
| 2026-02-25 | 9.80x |
| 2026-02-24 | 9.77x |
| 2026-02-23 | 9.75x |
| 2026-02-20 | 9.85x |
| 2026-02-19 | 9.87x |
| 2026-02-18 | 9.83x |
| 2026-02-17 | 9.64x |
| 2026-02-13 | 9.38x |
| 2026-02-12 | 10.52x |
| 2025-10-28 | 14.62x |
| 2025-10-27 | 14.85x |
| 2025-10-24 | 14.99x |
| 2025-10-23 | 14.95x |
| 2025-10-22 | 14.76x |
| 2025-10-21 | 14.66x |
| 2025-10-20 | 14.28x |
| 2025-10-17 | 13.81x |
| 2025-10-16 | 13.91x |
| 2025-10-15 | 13.65x |
| 2025-10-14 | 13.62x |
| 2025-10-13 | 13.56x |
| 2025-10-10 | 13.32x |
| 2025-10-09 | 13.44x |
| 2025-10-08 | 13.53x |
| 2025-10-07 | 13.28x |
| 2025-10-06 | 13.78x |
| 2025-10-03 | 13.63x |
| 2025-10-02 | 13.19x |
| 2025-10-01 | 13.33x |
| 2025-09-30 | 12.64x |
| 2025-09-29 | 12.23x |
| 2025-09-26 | 12.28x |
| 2025-09-25 | 12.24x |
| 2025-09-24 | 12.49x |
| 2025-09-23 | 12.70x |
| 2025-09-22 | 12.76x |
| 2025-09-19 | 12.78x |
| 2025-09-18 | 12.88x |
| 2025-09-17 | 12.63x |
| 2025-09-16 | 12.71x |
| 2025-09-15 | 12.63x |
| 2025-09-12 | 12.64x |
| 2025-09-11 | 12.86x |
| 2025-09-10 | 12.50x |
| 2025-09-09 | 12.86x |
| 2025-09-08 | 13.03x |
| 2025-09-05 | 13.23x |
| 2025-09-04 | 13.00x |
| 2025-09-03 | 12.94x |
| 2025-09-02 | 13.05x |
| 2025-08-29 | 13.33x |
| 2025-08-28 | 13.16x |
| 2025-08-27 | 13.13x |
| 2025-08-26 | 13.28x |
| 2025-08-25 | 13.31x |
| 2025-08-22 | 13.57x |
| 2025-08-21 | 12.82x |
| 2025-08-20 | 12.95x |
| 2025-08-19 | 12.95x |
| 2025-08-18 | 12.81x |
| 2025-08-15 | 12.85x |
| 2025-08-14 | 12.91x |
| 2025-08-13 | 12.91x |
| 2025-08-12 | 12.41x |
| 2025-08-11 | 12.01x |
| 2025-08-08 | 12.00x |
| 2025-08-07 | 12.04x |
| 2025-08-06 | 12.00x |
| 2025-08-05 | 12.31x |
| 2025-08-04 | 12.49x |
| 2025-08-01 | 12.80x |
| 2025-07-31 | 11.11x |
| 2024-02-15 | 167.75x |
| 2024-02-14 | 167.37x |
| 2024-02-13 | 161.88x |
| 2024-02-12 | 166.62x |
| 2024-02-09 | 166.12x |
| 2024-02-08 | 166.53x |
| 2024-02-07 | 166.09x |
| 2024-02-06 | 166.02x |
| 2024-02-05 | 163.10x |
| 2024-02-02 | 163.89x |
| 2024-02-01 | 167.86x |
| 2024-01-31 | 164.11x |
| 2024-01-30 | 169.46x |
| 2024-01-29 | 168.36x |
| 2024-01-26 | 167.90x |
| 2024-01-25 | 161.98x |
| 2024-01-24 | 162.10x |
| 2024-01-23 | 161.49x |
| 2024-01-22 | 160.37x |
| 2024-01-19 | 157.48x |
| 2024-01-18 | 156.31x |
| 2024-01-17 | 156.32x |
| 2024-01-16 | 161.47x |
| 2024-01-12 | 163.03x |
| 2024-01-11 | 164.08x |
| 2024-01-10 | 164.05x |
| 2024-01-09 | 162.66x |
| 2024-01-08 | 164.61x |
| 2024-01-05 | 162.01x |
| 2024-01-04 | 162.06x |
| 2024-01-03 | 163.16x |
| 2024-01-02 | 167.41x |
| 2023-12-29 | 165.04x |
| 2023-12-28 | 165.84x |
| 2023-12-27 | 164.69x |
| 2023-12-26 | 164.13x |
| 2023-12-22 | 164.04x |
| 2023-12-21 | 163.49x |
| 2023-12-20 | 158.26x |
| 2023-12-19 | 161.45x |
| 2023-12-18 | 158.09x |
| 2023-12-15 | 157.25x |
| 2023-12-14 | 159.97x |
| 2023-12-13 | 161.03x |
| 2023-12-12 | 151.97x |
| 2023-12-11 | 156.29x |
| 2023-12-08 | 156.32x |
| 2023-12-07 | 159.13x |
| 2023-12-06 | 159.39x |
| 2023-12-05 | 157.09x |
| 2023-12-04 | 158.55x |
| 2023-12-01 | 157.66x |
| 2023-11-30 | 156.69x |
| 2023-11-29 | 156.49x |
| 2023-11-28 | 156.45x |
| 2023-11-27 | 157.72x |
| 2023-11-24 | 159.60x |
| 2023-11-22 | 158.99x |
| 2023-11-21 | 157.28x |
| 2023-11-20 | 156.50x |
| 2023-11-17 | 154.11x |
| 2023-11-16 | 156.49x |
| 2023-11-15 | 157.60x |
| 2023-11-14 | 157.88x |
| 2023-11-13 | 156.15x |
| 2023-11-10 | 156.28x |
| 2023-11-09 | 157.55x |
| 2023-11-08 | 156.79x |
| 2023-11-07 | 155.71x |
| 2023-11-06 | 149.23x |
| 2023-11-03 | 148.78x |
| 2023-11-02 | 145.67x |
| 2023-11-01 | 143.95x |
| 2023-10-31 | 142.92x |
| 2023-10-30 | 140.18x |
| 2023-10-27 | 140.79x |
| 2022-04-28 | 2.70x |
| 2022-04-27 | 2.63x |
| 2022-04-26 | 2.59x |
| 2022-04-25 | 2.79x |
| 2022-04-22 | 2.81x |
| 2022-04-21 | 2.87x |
| 2022-04-20 | 2.96x |
| 2022-04-19 | 2.93x |
| 2022-04-18 | 2.85x |
| 2022-04-14 | 2.88x |
| 2022-04-13 | 2.97x |
| 2022-04-12 | 2.94x |
| 2022-04-11 | 3.11x |
| 2022-04-08 | 3.15x |
| 2022-04-07 | 3.14x |
| 2022-04-06 | 3.04x |
| 2022-04-05 | 3.03x |
| 2022-04-04 | 3.00x |
| 2022-04-01 | 3.00x |
| 2022-03-31 | 2.96x |
| 2022-03-30 | 3.05x |
| 2022-03-29 | 3.06x |
| 2022-03-28 | 3.02x |
| 2022-03-25 | 2.97x |
| 2022-03-24 | 2.99x |
| 2022-03-23 | 2.98x |
| 2022-03-22 | 3.10x |
| 2022-03-21 | 3.05x |
| 2022-03-18 | 3.10x |
| 2022-03-17 | 3.03x |
| 2022-03-16 | 2.96x |
| 2022-03-15 | 2.89x |
| 2022-03-14 | 2.85x |
| 2022-03-11 | 2.79x |
| 2022-03-10 | 2.85x |
| 2022-03-09 | 2.92x |
| 2022-03-08 | 2.76x |
| 2022-03-07 | 2.89x |
Showing the most recent 260 of 4,221 data points. The chart above shows the full history.
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz